German pharmaceutical factories team up to fix EU vaccine shortfall
Ryan Thompson in Frankfurt
The world's pharmaceutical companies often compete to develop and distribute treatments. But amid a critical shortfall of COVID-19 vaccines across the EU, rivals have begun to team up to manufacture more doses as fast as possible.
Germany has become the epicenter of these efforts thanks to the nation's strong network of biotech firms and production sites. At least seven factories in the country will soon produce EU-approved vaccines for Pfizer-BioNTech and AstraZeneca.
"We believe in the importance of maintaining high quality and secure delivery for Europe, especially in case of a crisis," said Hans-Georg Feldmeier, CEO of Germany's DermaPharm.
DermaPharm joins French-giant Sanofi, in offering to use German factories to produce millions of extra doses of the Pfizer jab by the summer.